News
Is This a Good Sign for Novavax?
Novavax (NASDAQ: NVAX) shares soared more than 30% in one trading session this week. That's a huge gain for any stock. But it's particularly impressive for Novavax. The biotech stock has been in the
Why Shares of Novavax Are Up Monday
Shares of Novavax (NASDAQ: NVAX) were up more than 24% as of 12:08 p.m. ET on Monday after the biotech company said Friday that Canada will pay $349.6 million for unused COVID-19 shots from the
Why Shares of CareDx Are Jumping Friday
Shares of transplant diagnostics company CareDx (NASDAQ: CDNA) were up more than 20% as of 12:20 p.m. ET on Friday after a decision by the Centers for Medicare & Medicaid Services (CMS) that could
1 Cathie Wood Stock That Could Double Your Money
Cathie Wood's Ark Investment Management has deemed CRISPR/Cas 9 genome editing as "biotech's breakthrough of the century." Back in 2018, Ark identified this gene-editing tool as a potential $2
Why Shares of CymaBay Therapeutics Are Soaring Friday
Shares of CymaBay Therapeutics (NASDAQ: CBAY) were up more than 37% as of 11:15 a.m. ET on Friday. The clinical-stage biotech saw its shares rise after Ipsen and Genfit announced phase 3 trials data
Why Shares of CorMedix Are Slumping Thursday
Shares of CorMedix (NASDAQ: CRMD) were down more than 21% as of noon ET on Thursday. The shares fell after the company announced a stock sale. The healthcare stock is down more than 5% so far this
This 1 Problem Could Sink at Least 4 Gene-Editing Stocks
What do CRISPR Therapeutics (NASDAQ: CRSP), Bluebird Bio (NASDAQ: BLUE), Editas Medicine (NASDAQ: EDIT), and Intellia Therapeutics (NASDAQ: NTLA) all have in common? If you said, "They're biotechs
Better Buy: Nano-X Imaging vs. Viking Therapeutics
Viking Therapeutics (NASDAQ: VKTX) and Nano-X Imaging (NASDAQ: NNOX) are two small-cap healthcare companies with lots of potential, but their shares come with some hefty risks. They've also both
Why Shares of Axsome Therapeutics Fell Wednesday
Shares of Axsome Therapeutics (NASDAQ: AXSM) were down more than 10% as of 3:45 p.m. ET Wednesday after the company announced it is offering 3 million shares at $75 each in a stock sale worth $225
As the Bull Roars, Shareholders Hate How These 2 Companies Are Selling Their Stock
The stock market has treated investors well so far in 2023, and although the past couple of weeks have been a bit more turbulent, the Nasdaq Composite (NASDAQINDEX: ^IXIC) gave Wall Street a gain of
2 Under-the-Radar Biotech Stocks to Buy in 2023
There are plenty of well-known biotech giants that look like solid investments. But targeting smaller and relatively unknown companies in the industry could provide much juicier returns over the
Why Viking Therapeutics Is Plunging Today
Clinical-stage biotech Viking Therapeutics (NASDAQ: VKTX) is having another tough trading session. As of 1:40 p.m. ET Tuesday, Viking's stock was down by 19.8% on higher-than-normal volume
Why Viking Therapeutics Stock Is Crashing Today
Viking Therapeutics' (NASDAQ: VKTX) shares were down by 9.9% on heavy volume as of 11:14 a.m. ET on Monday. This sizable drop was due to Pfizer's (NYSE: PFE) announcement that it will advance its
2 Low-Priced Stocks That Could Make You Richer
Buying low-priced growth stocks ($10 or below) can be risky. Companies with bargain-basement share prices tend to have weak balance sheets, highly uncertain outlooks, and limited financing
UFC: The Story of a Corporate Turnaround
Michael Thomsen is the author of Cage Kings: How an Unlikely Group of Moguls, Champions, and Hustlers Transformed the UFC Into a $10 Billion Industry.
Motley Fool host Ricky Mulvey caught up with
3 Monster Stocks in the Making to Buy Right Now
What's small today could become huge in the future. That's especially true in the high-stakes world of biopharmaceutical companies. Three Fool.com contributors identified what they believe could be
Wall Street Expects Intellia Therapeutics Stock to Climb 107%. Is That Too Optimistic?
Sometimes even the professionals put the horse before the cart. For instance, Wall Street analysts are currently predicting that shares of the gene editing therapy biotech Intellia Therapeutics
Cathie Wood Is Buying This Growth Stock and Selling Its Competitor. Should You Follow Suit?
Over the last couple of weeks, Cathie Wood's ARK Innovation ETF has been busy buying shares of gene-editing biotech Intellia Therapeutics (NASDAQ: NTLA). She's also been selling some shares of
After Blasting Off 881% in 1 Year, Is Viking Therapeutics Still a Good Buy?
Viking Therapeutics (NASDAQ: VKTX) is up 881% in the last 12 months thanks to its ongoing development of a pair of therapies to treat obesity and metabolic disorders like diabetes. As you may have
Where Will Axsome Therapeutics Be in 3 Years?
Last year was a big one for Axsome Therapeutics (NASDAQ: AXSM). The biotech company specialized in central nervous system conditions launched its first two products and saw its share price increase
What Do Bears Know About Novavax That Bulls Don't?
Novavax (NASDAQ: NVAX) soared early in the coronavirus vaccine race. The stock climbed more than 2,700% in 2020.
But as the biotech company fell behind in the race, so did its shares. Novavax
If You Own These 3 Growth Stocks, You Might Want to Rethink Your Position
Nano-X Imaging (NASDAQ: NNOX), DermTech (NASDAQ: DMTK), and Viking Therapeutics (NASDAQ: VKTX) are healthcare growth stocks with plenty of potential, little revenue, and a boatload of risk.
Share
Intellia Therapeutics Stock Could Roar in the Next Bull Market. Here's Why.
Even after rising 30% so far this year, shares of Intellia Therapeutics (NASDAQ: NTLA) could easily experience another leg up if there's a bull market in the latter half of 2023. With positive
3 Cathie Wood Investments That Could Deliver Superior Returns
Cathie Wood, the CEO of Ark Investment, has made a name for herself by betting on cutting-edge technology with financial technology stocks, or fintechs, and biotechnology growth stocks making up a
Could Viking Therapeutics Stock Help You Become a Millionaire?
An up-and-coming stock with lots of potential is Viking Therapeutics (NASDAQ: VKTX). Investors have been piling money into the biotech stock this year, as it has surged 150% since January. And at a